Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and ...

Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of ...

AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer diagnostics ...

A new Stanford blood test detects cancer and tissue damage by analyzing rare RNA fragments in the blood. Stanford Medicine ...

GOSSELIES, Belgium, April 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation ...